Erasca, Inc. filed an 8-K on November 20, 2026, disclosing updated U.S. Phase 1 interim clinical data for pan-RAS molecular glue ERAS-0015 and preliminary data for pan-KRAS inhibitor ERAS-4001, along with an accelerated timeline for a Phase 3 trial in first-line pancreatic cancer.
Key Highlights
- 69% confirmed ORR in PDAC: ERAS-0015 at 32 mg QD achieved a 69% confirmed objective response rate in patients (N=13) with KRAS G12D or G12V pancreatic ductal adenocarcinoma, with 77% of those patients treated in the third-line or later setting.
- 44% confirmed ORR across all KRAS G12X PDAC: Across all patients (N=25) with KRAS G12X mutations in the 2L+ PDAC setting, the confirmed ORR was 44%; 84% of those patients were treated in 3L+ and 44% had G12R mutations.
- 60% confirmed ORR in NSCLC: At 32 mg QD in the 2L/3L post-ICI/platinum setting, ERAS-0015 achieved a 60% confirmed ORR (N=5) in KRAS G12X non-small cell lung cancer patients.
- Phase 3 timeline accelerated: According to the filing, Erasca is accelerating the planned initiation of a Phase 3 trial in first-line pancreatic cancer to the first half of 2027.
- No dose discontinuations at 32 mg QD: At the 32 mg QD dose (N=54), treatment-related adverse events led to dose interruptions in 13.0% of patients and dose reductions in 16.7%, with no dose discontinuations (0% of patients).
- ERAS-4001 preliminary data: As of November 9, 2026, ERAS-4001 showed favorable safety and tolerability with predominantly low-grade adverse events and no treatment-related adverse events leading to treatment discontinuation, according to the filing.
- Grade 5 TRAE previously disclosed: The filing notes that one Grade 3 pneumonitis event, first disclosed in April 2026, progressed to Grade 5 after withdrawal of supportive care per patient decision; no additional Grade 5 treatment-related adverse events have occurred.
ERAS-0015 Interim Data and Phase 3 Acceleration for Erasca
Erasca, Inc. (NASDAQ:ERAS), a clinical-stage oncology company based in San Diego, California, filed an 8-K under Item 8.01 on November 20, 2026, reporting updated data from its ongoing AURORAS-1 U.S. Phase 1 trial of ERAS-0015 and preliminary findings for ERAS-4001. The data cutoff date for ERAS-0015 monotherapy and combination results was September 1, 2026, while combination data carried a cutoff of October 14, 2026, and ERAS-4001 data were as of November 9, 2026.
At pharmacologically active doses of 16-32 mg once daily (N=122), the filing states ERAS-0015 "was generally well-tolerated with favorable safety data." The most common treatment-related adverse event across all patients at the pharmacologically active dose range was rash, occurring in 99 of 122 patients (81.1% all grades). Diarrhea was reported in 39 of 122 patients (32.0% all grades), nausea in 29 of 122 (23.8%), and stomatitis in 26 of 122 (21.3%). Median relative dose intensity at 32 mg QD was 100%, according to the filing. In biliary tract cancer, the filing reports a 75% confirmed ORR (N=4) at 32 mg QD in the 1L+ setting, and notes that RAS mutations occur in approximately 17% of BTC patients, with the company estimating approximately 5,000 U.S. patients and approximately 45,000 patients outside the United States diagnosed with RAS-mutant BTC annually.
Combination arms of ERAS-0015 with gemcitabine plus nab-paclitaxel, pembrolizumab, and panitumumab each cleared their respective DLT windows without dose-limiting toxicities at the reported cohorts, the filing disclosed. For ERAS-0015 plus panitumumab in KRAS G12X colorectal cancer, 2 ongoing confirmed partial responses were observed in 2 patients treated at 24 mg QD who then dose-reduced to 16 mg QD, and 1 unconfirmed partial response was seen in 4 patients at 16 mg QD. The company stated that nonclinical data show ERAS-0015 and ERAS-4001 together "targets both active- and inactive-state KRAS and exhibits synergistic activity in KRAS G12X-driven models."
What Was Disclosed
Erasca's November 20, 2026 8-K disclosed updated Phase 1 interim efficacy and safety data for ERAS-0015 across multiple tumor types, early combination data with three regimens, preliminary ERAS-4001 Phase 1 findings, and an accelerated Phase 3 start for first-line pancreatic cancer to the first half of 2027.




Please wait processing your request...